06 Oct 2026, 08:47 IST
Molbio Diagnostics Limited
Motilal Oswal Financial Services Ltd. (MOFSL) · BUY · target INR 1,800
The initiating coverage section says Molbio's Truenat point-of-care molecular platform, with 12,500+ devices across 90+ countries and 43 assays, plus digital pathology expansion, should drive an estimated 23% revenue CAGR and 50% PAT CAGR over FY26-29, with 19% upside from CMP INR1,503.
From MOStMarketOutlook06102026, written by Motilal Oswal Financial Services Ltd. (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal Financial Services Ltd. (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.